The clinical trial collaboration with ECOG-ACRIN is a positive pipeline catalyst but does not change the near-term financial trajectory. Monitor ESMO 2026 presentation of HARMONi-GI1 data on Oct 25 for potential stock-moving efficacy details. The EPS miss is notable but typical for a pre-revenue biotech; focus on clinical milestones rather than quarterly earnings.
Price Chart
Executive Summary
Akeso announced that its partner Summit Therapeutics (SMMT) initiated a Phase II/III registrational trial (EA2251) for ivonescimab in first-line biliary tract cancer with ECOG-ACRIN, the 7th international registrational trial for the drug. This expands ivonescimab's clinical program into a new indication with a positive prior Phase III readout (HARMONi-GI1) in BTC. Separately, SMMT reported Q2 2026 EPS of -$0.28, missing consensus of -$0.21 by 34%, with revenue of $54K (essentially pre-revenue).
Key Financial Metrics
Key Facts
- Summit Therapeutics and ECOG-ACRIN initiated a registration-enabling Phase II/III study (EA2251) of ivonescimab in first-line biliary tract cancer.
- This is the 7th international registrational Phase II/III trial for ivonescimab.
- Prior Phase III HARMONi-GI1 study in BTC achieved a positive and clinically meaningful overall survival result.
- Clinical trial site activations in the U.S. expected to begin Q4 2026.
- SMMT reported Q2 2026 EPS of -$0.28, missing consensus of -$0.21 (34% miss).
- Revenue for Q2 2026 was $54K, consistent with pre-revenue stage.
Financial Impact
Q2 2026 EPS miss of 34% vs consensus; revenue negligible at $54K. Clinical trial expansion has no near-term revenue impact but adds pipeline optionality.
Risk Factors
- Ivonescimab may fail to show statistically significant efficacy in the BTC trial.
- Regulatory approval and commercialization timelines remain uncertain.
- SMMT has no approved products and relies on partnership with Akeso; any disruption could materially impact valuation.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302915469 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Press Release | $15.83 $15.55 | ▼ −1.77% | ▼ −0.59% | $14.50 (−8.40%) |
Oct 19, 2026 7d ago | DEF 14A | $15.57 $16.09 | ▲ +3.34% | ▲ +3.00% | $14.50 (−6.87%) |
Sep 28, 2026 27d ago | 8-K | $16.39 $16.91 | ▲ +3.17% | ▲ +3.38% | $14.50 (−11.53%) |
Sep 15, 2026 5w ago | 8-K | $17.40 $17.54 | ▲ +0.80% | ▲ +0.48% | $14.50 (−16.67%) |
Sep 14, 2026 6w ago | 8-K | $18.42 $17.40 | ▼ −5.54% | ▼ −5.08% | $14.50 (−21.28%) |
Sep 3, 2026 7w ago | 8-K | $17.13 $17.61 | ▲ +2.77% | ▲ +3.16% | $14.50 (−15.35%) |
Aug 26, 2026 8w ago | 8-K | $14.23 $14.33 | ▲ +0.70% | ▲ +0.05% | $14.50 (+1.90%) |
Aug 5, 2026 11w ago | 8-K | $13.53 $13.54 | ▲ +0.07% | ▲ +0.23% | $14.50 (+7.17%) |
Jul 22, 2026 13w ago | 8-K | $14.74 $14.98 | ▲ +1.63% | ▲ +2.86% | $14.50 (−1.63%) |
Jun 12, 2026 19w ago | Insider Cluster | $14.01 $14.13 | ▲ +0.86% | ▼ −0.91% | $14.50 (+3.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers